IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence
MWN-AI** Summary
The European Institute of Oncology (IEO) and Laife Reply have partnered to launch "Bianca," Italy’s first large-scale AI-driven digital biobank aimed at revolutionizing the pathology diagnostic process. This initiative focuses on the digitalization of histopathological samples, thus enabling the training of AI algorithms to assist pathologists in diagnostic activities. By transitioning from traditional workflows to a fully digital ecosystem, the project enhances efficiency, scalability, and reproducibility in oncological diagnostics.
Bianca is part of a broader integration of research and development within clinical diagnostic practices, and it leverages cutting-edge imaging technology to generate ultra-high-resolution digital representations of tissue samples. The collaboration ensures that AI algorithms are trained to analyze these images, thereby aiding clinical diagnostics while also streamlining the workflow process. Launched in late 2024, the project is currently midway through its 30-month timeline, with significant advancements in digitizing IEO's vast archive of histopathological samples.
A key component of Bianca's AI framework includes self-annotation mechanisms, which automatically label findings on images, thereby easing the clinician's workload and accelerating model training. Furthermore, the project is evolving multimodal algorithms designed to combine histopathological images with clinical data to identify novel biomarkers, potentially transforming the predictive capability of diagnostics.
Professor Nicola Fusco from IEO remarked that Bianca signifies a pivotal shift in oncological pathology, emphasizing quality and efficiency improvements. Laife Reply's Carlo Malgieri articulated the goal of establishing a scalable framework that integrates digitalization, advanced algorithms, and high-performance analytics to enhance oncological care and research, ensuring trustworthy AI-supported decisions.
MWN-AI** Analysis
The collaboration between the European Institute of Oncology (IEO) and Laife Reply to launch “Bianca,” Italy’s first large-scale digital biobank, represents a pivotal advancement in oncological diagnostics and an attractive opportunity for investors looking to enter the growing healthcare technology sector. This initiative aims to transform traditional histopathological workflows into a fully digital and AI-supported ecosystem, enhancing diagnostic efficiencies and accuracy.
Investors should note the increasing significance of AI in healthcare, particularly as it pertains to pathology. The project’s integration of AI algorithms capable of analyzing histopathological images and aiding in clinical hypothesis formulation indicates a shift toward more systematic and data-driven approaches in medical diagnostics. This aligns with global trends of digitization in healthcare, driven by the need for improved diagnostic capabilities and personalized medicine.
As the project progresses through its planned 30-month duration, investors should be aware of the scalability aspect emphasized by Laife Reply. The framework they are developing is designed not just for large hospitals but also for smaller healthcare organizations, which may widen the market reach and increase adoption rates across various medical institutions. This scalability is crucial considering the increasing pressure on healthcare systems worldwide to improve outcomes while managing costs.
Moreover, the comprehensive digitalization of the IEO’s extensive archive of historical samples opens avenues for groundbreaking research and biomarker identification, indicating long-term value creation in the oncological field. Given these factors, analysts encourage monitoring both companies as they advance their project. The combination of state support under Italy's “Agreements for Innovation” program and the establishment of a synergy between research and practical application positions this initiative as a potential game-changer in oncological diagnostics and a key investment opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities.
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply , the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca , the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice . The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/
On this platform, Artificial Intelligence algorithms are developed and trained to analyse images and support pathologists in histological and molecular analysis, as well as in the formulation of clinical and diagnostic hypotheses.
Selected under the “Agreements for Innovation” programme promoted by the Italian Ministry of Enterprises and Made in Italy (MIMIT), and building on a well-established collaboration between IEO and Reply, the BIANCA project initially involves the digitalisation of histopathological slides using state-of-the-art scanners capable of generating ultra-high-resolution digital images of tissue samples. On this platform, Artificial Intelligence algorithms are developed and trained to analyse images and support pathologists in histological and molecular analysis, as well as in the formulation of clinical and diagnostic hypotheses.
Launched at the end of 2024 with a planned overall duration of 30 months, the project has now reached its midway point. The extensive archive of histopathological samples collected over the years by the IEO Biobank is currently at an advanced stage of digitalisation. At the same time, Laife Reply is working closely with the joint IEO Pathology and Information Systems team to train AI algorithms on different types of cancer. This includes the introduction of advanced algorithmic solutions based on self-annotation mechanisms , capable of automatically labelling pathological findings on images, reducing the manual workload for clinicians, accelerating model training, improving accuracy and enabling large-scale replicability.
The project is also exploring the use of multimodal algorithms capable of combining histopathological images with structured clinical data to identify and analyse new biomarkers. In particular, research activities are already underway on specific diseases, with the aim of predicting information that is currently obtainable only through complex tests, thereby reducing time, costs and the overall impact on patients.
“ Bianca represents a turning point for oncological pathology,” said Professor Nicola Fusco , Director of the Pathology Division at IEO . “The integration of digitalisation and AI enables a significant improvement in the quality, standardisation and reproducibility of diagnosis—both histopathological and molecular—by optimising the entire workflow, reducing reporting times, rationalising costs and improving the overall efficiency of diagnostic services for our patients. At the same time, the project contributes to the training of a new generation of pathologists with highly specialised skills, capable of combining morphological and molecular expertise with advanced digital tools and AI algorithms, paving the way for a sustainable evolution of oncological diagnostics.”
“ With Bianca, we are collaborating with IEO to support the evolution of pathology in the oncological field,” said Carlo Malgieri, Partner at Laife Reply . “This is not just about applying artificial intelligence to individual cases, but about building a scalable and industrialisable framework designed to be offered to hospitals and smaller healthcare organisations. The framework integrates sample digitalisation, advanced algorithms and high-performance analytics infrastructures. This approach makes it possible to support clinicians, enable new services for healthcare systems and oncological research, and ensure transparency and explainability—key elements to guarantee that every algorithm-supported decision is trustworthy.”
Laife Reply
Laife Reply is a Reply Group company operating in the Health, Welfare and Pharma sectors. It develops Artificial Intelligence solutions ranging from Medical Imaging, Drug Discovery and Digital Therapeutics to Natural Language Processing for the analysis of unstructured data. https://www.reply.com/laife-reply/en
IEO - Istituto Europeo di Oncologia
The European Institute of Oncology (IEO) is a Scientific Institute for Research, Hospitalisation and Healthcare (IRCCS) and an international reference centre in the field of oncology. The Institute has developed an innovative care model based on key principles such as patient centrality, full integration between research and clinical activity, early diagnosis and prevention. This is complemented by a data-driven strategy , enabling the rapid development of Artificial Intelligence algorithms to accelerate diagnosis and improve the efficiency of therapeutic pathways. https://www.ieo.it/en/
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260210610418/en/
Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
IEO - Istituto Europeo di Oncologia
Donata Francese
Donata.francese@dfpress.it
Tel + 39 02 535761
FAQ**
How does the Bianca project leverage AI technologies to enhance the efficiency and accuracy of the histopathological sample analysis process, particularly in relation to the business model of Reply SpA (Italy) RPYTF?
What specific advanced algorithmic solutions are being implemented in the Bianca project to reduce manual workloads for clinicians, and how does this approach align with the strategic goals of Reply SpA (Italy) RPYTF?
In what ways will the digital biobank created through the Bianca initiative impact future research and clinical practices in oncology, and how does this reflect the innovative vision of Reply SpA (Italy) RPYTF?
Can you elaborate on the scalability and industrializability of the Bianca project, especially regarding its potential applications for hospitals and smaller healthcare organizations linked to the offerings of Reply SpA (Italy) RPYTF?
**MWN-AI FAQ is based on asking OpenAI questions about Reply SpA (Italy) (OTC: RPYTF).
NASDAQ: RPYTF
RPYTF Trading
291.63% G/L:
$131.785 Last:
269 Volume:
$131.785 Open:
